In order to further verify the clinical significance of increased ECT2 for breast cancer patients, we interrogated the relationship between ECT2 expression and clinic-pathologic parameters, including TNM stage (based on tumor size, lymph node involvement and distant metastasis), and molecular subtype. Here, ECT2 is linked to breast cancer.